Edwards Lifesciences Corporation
Edwards Lifesciences Corporation’s revenue for fiscal 2025 (year ended December 2025) was $6.1 billion, up 11.5% from fiscal 2024. In the quarter to June 2026, revenue grew 13.6%, EPS fell 26.3%, free cash flow grew 142.8% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for three consecutive years.
Follow EW
Edwards Lifesciences Corporation (EW) P/B ratio
As of 16 October 2026, Edwards Lifesciences Corporation (EW) trades at a P/B ratio of 4.7×. Over the past ten years it has ranged from 3.9× (April 2025) to 14.9× (September 2021); the current reading is higher than 12% of that period. That is above the Medical Devices industry median of 2.3× and above the Healthcare sector median of 2.3×.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 4.8× | 9.68% |
| FY2024 | 4.4× | (35.56%) |
| FY2023 | 6.8× | (13.82%) |
| FY2022 | 7.9× | (42.78%) |
| FY2021 | 13.8× | 11.43% |
| FY2020 | 12.4× | 6.02% |
| FY2019 | 11.7× | 14.78% |
| FY2018 | 10.2× | 28.20% |
| FY2017 | 8.0× | 2.46% |
| FY2016 | 7.8× | 14.23% |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Jun 2026 | 4.9× | 8.25% |
| Mar 2026 | 4.5× | (6.87%) |
| Dec 2025 | 4.8× | 8.23% |
| Sep 2025 | 4.5× | 2.95% |
| 42 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| ZBH Zimmer Biomet Holdings, Inc. compare | 1.4× |
| PHG Koninklijke Philips N.V. compare | 1.8× |
| MDT Medtronic PLC compare | 2.4× |
| BSX Boston Scientific Corporation compare | 2.6× |
| GEHC GE HealthCare Technologies Inc. compare | 2.9× |
| STE STERIS plc compare | 3.0× |
| EW Edwards Lifesciences Corporation | 4.7× |
| SYK Stryker Corporation compare | 4.7× |
| DXCM DexCom, Inc. compare | 12.5× |
| Medical Devices industry median | 2.3× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on EW
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement